Medical device maker BD (Becton Dickinson) has withdrawn from talks aimed at resolving a dispute over severance packages for ...

BD (NYSE:BDX) shares ticked up before hours today on fourth-quarter results that came in ahead of the consensus forecast.

Josh Jennings, an analyst from TD Cowen, maintained the Hold rating on Becton Dickinson (BDX – Research Report). The associated price ...

China remains an attractive market despite global economic uncertainties, a top executive participating in the ongoing ...

These factors can help drive innovation in the healthcare industry and contribute Chinese wisdom and solutions to global ...

BD's Q4 sales rose 6.9% to $5.44 billion, beating estimates. EPS of $3.81 also topped forecasts. FY25 guidance includes $21.9 ...

BD Medical segment sales increased to $2.84 billion, up 11.1%. Medication Management Solutions led organic revenue growth of 8.6%. BD Life Sciences sales were almost flat to $1.34 billion ...

Becton Dickinson and Co Michael Garrison; Executive Vice President, President - Medical Segment; Becton Dickinson and Co Hello, and welcome to BD's fourth-quarter and full year fiscal 2024 ...

Begin your TipRanks Premium journey today. Becton Dickinson (BDX) Company Description: Founded in 1897, Becton, Dickinson & Co. is a New Jersey-based medical technology company. The company develops, ...

Here is how Becton Dickinson performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts: Revenues- BD Medical- Medication Management ...